BRISTOL PRAVACHOL SALES INCREASE 47% TO $255 MIL. WORLDWIDE IN FIRST QUARTER
Executive Summary
Bristol-Myers Squibb's Pravachol (pravastatin) sales increased 47% worldwide to $255 mil. in the first quarter, the company reported April 23. The HMG-CoA reductase inhibitor benefitted from clinical studies showing long-term efficacy of the cholesterol-lowering agent, Bristol-Myers Squibb remarked